Verona Pharma Plc : Pdmr Dealing & Issue Of Shares

 
TIDMVRP 
 
   LONDON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on August 9, 2018, Dr. David 
Ebsworth, Chairman of the Company, purchased 12,000 ordinary shares of 5 
pence each in the Company (the "Ordinary Shares") at a price of 120.00 
pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will 
have an interest in the Company of 147,787 Ordinary Shares, representing 
0.14% of the Company's issued share capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
   The Company also announces that, on August 9, 2018, it issued 58,112 new 
Ordinary Shares (the "New Ordinary Shares") following the vesting of 
restricted stock units held by a former employee, Dr. Ken Newman. 
Application will be made to the London Stock Exchange for the New 
Ordinary Shares to be admitted to trading on AIM, with dealings expected 
to commence on 16 August 2018 ("Admission"). Following Admission, the 
Company will have a total of 105,075,513 Ordinary Shares in issue each 
carrying one voting right. The Company does not hold any Ordinary Shares 
in Treasury. This figure of 105,075,513 Ordinary Shares may be used by 
shareholders as the denominator for the calculations by which they will 
determine if they are required to notify their interest in, or a change 
to their interest in, the share capital of the Company under the FCA's 
Disclosure and Transparency Rules. 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------------- 
a)  Name                     David Ebsworth 
 
2   Reason for the notification 
    ---------------------------------------------------------------------------- 
a)  Position/status          Chairman 
 
b)  Initial                  Initial notification 
    notification/Amendment 
 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------------- 
a)  Name                     Verona Pharma plc 
    -----------------------  --------------------------------------------------- 
b)  LEI                      213800EVI6O6J3TIAL06 
 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    ---------------------------------------------------------------------------- 
a)  Description of the       Ordinary Shares of 5 pence each 
    financial instrument, 
    type of instrument 
 
    Identification code      GB00BYW2KH80 
 
b)  Nature of the            David Ebsworth purchased 12,000 Ordinary Shares 
    transaction 
 
c)  Price(s) and volume(s)            Price(s)                Volume(s) 
                               -----------------------  ---------------------- 
                               120.00 pence per         12,000 Ordinary Shares 
                               Ordinary Share 
                               -----------------------  ---------------------- 
 
d)  Aggregated information   N/A 
 
    - Aggregated volume 
 
    - Price 
 
e)  Date of the transaction  9 August 2018 
    -----------------------  ------------------------------------------------- 
f)  Place of the             London Stock Exchange, AIM 
    transaction 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
 

(END) Dow Jones Newswires

August 10, 2018 07:12 ET (11:12 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.